Extracorporeal Photopheresis for Acute Graft Versus Host Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Graft Versus Host DiseaseCancerStem Cell Transplantation
Interventions
PROCEDURE

Extracorporeal Photopheresis

"ECP will be performed using the UVAR® XTS™ photopheresis system (Therakos). Whole blood is drawn and separated by centrifuge to collect the buffy coat (lymphocyte solution). Methoxsalen (8-MOP) is added to the blood, and the final solution of cells is passed as a film, 1mm thick, through a disposable plastic device, exposed to a UVA light source (2J/cm2/cell) and then returned to the patient.~ECP will be performed weekly on 2 consecutive days for 4 weeks. After 4 weeks the interval will be prolonged to every 2 weeks and ECP will be stopped after maximal response has been maintained for 2 weeks. The actual study finishes at d56 but ECP may be continued beyond that (off-study) at the discretion of the physician."

Trial Locations (1)

60611

Ann & Robert H Lurie Children's Hospital of Chicago, Chicago

All Listed Sponsors
lead

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER

NCT00179855 - Extracorporeal Photopheresis for Acute Graft Versus Host Disease | Biotech Hunter | Biotech Hunter